Treatment of specific macrovascular beds in patients with diabetes mellitus
- PMID: 20701768
- PMCID: PMC2925360
- DOI: 10.1186/1750-4732-4-5
Treatment of specific macrovascular beds in patients with diabetes mellitus
Abstract
In 2007, over 23 million people had diabetes in the United States and death from cardiovascular disease is estimated to occur in 80% of those Americans. Risk factor reduction is the most important therapy for primary and secondary prevention of macrovascular disease in patients with and without diabetes mellitus. Despite this, presentation and response to therapy is often different for patients with diabetes compared to their non-diabetic counterparts. This paper will review the current targets for therapy of cardiovascular disease, peripheral vascular disease, and cerebrovascular disease in patients with diabetes.
Figures

Similar articles
-
Macrovascular Complications of Type 2 Diabetes Mellitus.Curr Vasc Pharmacol. 2020;18(2):110-116. doi: 10.2174/1570161117666190405165151. Curr Vasc Pharmacol. 2020. PMID: 30961498 Review.
-
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.Prog Brain Res. 2002;139:289-98. doi: 10.1016/s0079-6123(02)39025-3. Prog Brain Res. 2002. PMID: 12436944 Review.
-
Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications.Am J Cardiol. 2011 Aug 2;108(3 Suppl):59B-67B. doi: 10.1016/j.amjcard.2011.03.017. Am J Cardiol. 2011. PMID: 21802582 Review.
-
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.Lancet. 2007 Sep 8;370(9590):829-40. doi: 10.1016/S0140-6736(07)61303-8. Lancet. 2007. PMID: 17765963 Clinical Trial.
-
Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.Cardiovasc Diabetol. 2016 Sep 2;15(1):129. doi: 10.1186/s12933-016-0446-x. Cardiovasc Diabetol. 2016. PMID: 27590190 Free PMC article. Clinical Trial.
Cited by
-
Progress on diabetic cerebrovascular diseases.Bosn J Basic Med Sci. 2014 Nov 9;14(4):185-90. doi: 10.17305/bjbms.2014.4.203. Bosn J Basic Med Sci. 2014. PMID: 25428668 Free PMC article. Review.
-
Coordinated Activation of VEGF/VEGFR-2 and PPARδ Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice.PLoS One. 2016 Dec 8;11(12):e0167305. doi: 10.1371/journal.pone.0167305. eCollection 2016. PLoS One. 2016. PMID: 27930695 Free PMC article.
-
Ibrutinib ameliorates cerebral ischemia/reperfusion injury through autophagy activation and PI3K/Akt/mTOR signaling pathway in diabetic mice.Bioengineered. 2021 Dec;12(1):7432-7445. doi: 10.1080/21655979.2021.1974810. Bioengineered. 2021. PMID: 34605340 Free PMC article.
-
ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease.Biomaterials. 2015 Feb;41:166-75. doi: 10.1016/j.biomaterials.2014.11.016. Epub 2014 Dec 9. Biomaterials. 2015. PMID: 25522975 Free PMC article.
References
-
- National Health and Nutrition Examination Survey III. Electronic References. http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx Retrieved December 30, 2009.
LinkOut - more resources
Full Text Sources